NewAmsterdam Pharma Company N.V.
NAMSHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. The $3.72B market capitalization puts NAMS squarely in mid-cap range for its industry. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Market Cap
$3.72B
Beta
0.03
P/E (TTM)
—
P/E (Fwd)
-24.56
EPS (TTM)
$-1.78
EPS (Fwd)
$-1.29
ROE
-29.5%
ROA
-17.3%
Cash
$636.1M
Total Debt
$23,000
Free CF
-$58.7M
52W Change
70.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $636.1M in cash comfortably exceeding the $23K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$58.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -29.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $102.7M (2022) to $22.5M (2025), a 78% decline worth watching.
NAMS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, NAMS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for NewAmsterdam Pharma Company N.V. and its sector.